116905-90-9

Basic information

• Product Name: N,N-diethyl-N-(piperidin-4-ylmethyl)amine
• Synonyms: N,N-diethyl-N-(piperidin-4-ylmethyl)amine;4-Piperidinemethanamine, N,N-diethyl-
• CAS NO: 116905-90-9
• Molecular Formula: C10H22 N2
• Molecular Weight: 170.3
• Mol File: 116905-90-9.mol

Chemical Properties

• Boiling Point: 218.7±8.0 °C(Predicted)
• Appearance: /
• Density: 0.865±0.06 g/cm3(Predicted)
• PKA: 10.54±0.10(Predicted)
• CAS DataBase Reference: N,N-diethyl-N-(piperidin-4-ylmethyl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diethyl-N-(piperidin-4-ylmethyl)amine(116905-90-9)
• EPA Substance Registry System: N,N-diethyl-N-(piperidin-4-ylmethyl)amine(116905-90-9)

Safety Data

• Hazardous Substances Data: 116905-90-9(Hazardous Substances Data)

Upstream product

• 95389-83-6 N,N-diethyl-4-piperidinecarboxamide hydrochloride 
• 144222-22-0 tert-butyl 4-(aminomethyl)piperidine-1-carboxylate 
• 1903-67-9 N,N-diethylpiperidine-4-carboxamide 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Downstream Products

• 1026865-57-5 2-Chloro-1-(4-diethylaminomethyl-piperidin-1-yl)-2,2-diphenyl-ethanone 

Relevant articles and documents

Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety

We herein report the design and synthesis of benzothiazinones containing a piperidine moiety as new antitubercular agents based on the structure feature of IMB-ZR-1 discovered in our lab. Some of them were found to have good in vitro activity (MIC 1 μg/

QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS

The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and nonneoplastic diseases.

Agents for the treatment of overactive detrusor. VI. Synthesis and pharmacological properties of acetamide derivatives bearing cyclic amines in N-substituents

With the aim of improving of the efficacy and decreasing the side effects of oxybutynin (1), N-[(tetrahydro-3- or 4-pyridyl)methyl]-, N-(4-piperidyl)- , and N-(3- or 4-piperidylalkyl)-2-hydroxyacetamides (3a-n, 4a-g) and the related carboxamides (3o-r, 4h-k, 13', 17) were synthesized and evaluated for inhibitory activity against urinary bladder rhythmic contraction in rats and for mydriatic activity in rats. Some of these compounds were superior to oxybutynin in both inhibitory activity against bladder contraction and selectivity between inhibitory activity against bladder contraction and mydriatic activity. Among them, N-[(1,2,3,6-tetrahydro-4-pyridyl)methyl]- and N-[(1,2,3,6-tetrahydro-1-methyl-4-pyridyl)methyl]-2-hydroxy-2,2- diphenylacetamide (3e, 3f) exhibited the most potent inhibitory activity against bladder contraction (ED30 = 0.005 and 0.003 mg/kg i.v., respectively). Judging from the effect of 3e on detrusor contraction in vitro in guinea-pigs, it appeared that the inhibitory activity of 3e against bladder contraction in vivo was related mainly to its inhibitory activity against detrusor contraction in vitro induced with carbacol (antimuscarine- like activity). The selectivity (20-fold) of 3e between inhibitory activity against bladder contraction and mydriatic activity was greatly superior to that (0.48-fold) of oxybutynin. Compound 3e was synthesized by debenzylation (method E or F) of the corresponding N-[[1-(4-methoxybenzyl)-tetrahydro-4- pyridyl]methyl] derivative (3k), which was prepared by acylation (method B) of the corresponding (tetrahydro-4-pyridyl)methylamine (7k) or by reduction (method D) of the corresponding pyridinium chloride (14k) with NaBH4.